Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update

$7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA trial for GelrinCAlready approved in Europe, GelrinC is expected to be rolled out in clinics across the …